Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126295631 | 12629563 | 1 | I | 20160729 | 20160808 | 20160808 | EXP | CA-PFIZER INC-2016371856 | PFIZER | 41.00 | YR | F | Y | 0.00000 | 20160808 | CN | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126295631 | 12629563 | 1 | PS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Subcutaneous | 25 MG, WEEKLY | 11719 | 25 | MG | SOLUTION FOR INJECTION | /wk | ||||||
| 126295631 | 12629563 | 2 | SS | SULFASALAZINE. | SULFASALAZINE | 1 | Oral | 1 G, 2X/DAY | 7073 | 1 | G | BID | |||||||
| 126295631 | 12629563 | 3 | SS | CELEBREX | CELECOXIB | 1 | Oral | 200 MG, 2X/DAY | 20998 | 200 | MG | CAPSULE, HARD | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126295631 | 12629563 | 1 | Rheumatoid arthritis |
| 126295631 | 12629563 | 2 | Rheumatoid arthritis |
| 126295631 | 12629563 | 3 | Rheumatoid arthritis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126295631 | 12629563 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126295631 | 12629563 | Tuberculin test positive |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |